Metabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related Morbidities

3

Min Seo Kim^{1,2,*}, Qiuli Chen^{3,4,5,*}, Yang Sui^{1,2,11,12*}, Xiong Yang^{3,4}, Shaoqi Wang^{3,4,5}, Lu-Chen
Weng^{1,2}, So Mi Jemma Cho^{1,2}, Satoshi Koyama^{1,2}, Xinyu Zhu^{3,4,6}, Kang Yu^{3,4,5}, Xingyu Chen^{3,4,5},
Rufan Zhang^{3,4}, Wanqing Yin^{3,4,5}, Shuangqiao Liao^{3,4,5}, Zhaoqi Liu^{3,4,5,6}, Fowzan S Alkuraya^{7,8,9},
Pradeep Natarajan^{1,2,10,11}, Patrick T. Ellinor^{1,2,11,12**}, Akl C. Fahed^{1,2,11,12**}, Minxian
Wang^{3,4,5,6,13,14,15**}

- 9
- 10 * co-first authors
- 11 ** co-senior authors
- 12

Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT
 and Harvard, Cambridge, MA, USA

- 15 2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
- 16 3. National Genomics Data Center, China National Center for Bioinformation, Beijing, China
- 17 4. Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
- 18 5. University of Chinese Academy of Sciences, Beijing, China
- College of Future Technology, Sino-Danish College, University of Chinese Academy of
 Sciences, Beijing, China
- 7. Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist
 Hospital and Research Center, Riyadh, Saudi Arabia
- 23 8. Lifera Omics, Riyadh, Saudi Arabia
- 24 9. College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
- 25 10. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 26 11. Harvard Medical School, Boston, MA, USA
- 27 12. Cardiology Division, Massachusetts General Hospital, Boston, MA, USA

13. Department of Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan,China

30 31	14. Hubei Provincial Engineering Research Center of Minimally Invasive Cardiovascular Surgery, Wuhan, China
32 33	15. Wuhan Clinical Research Center for Minimally Invasive Treatment of Structural Heart Disease, Wuhan, China.
34	
35	
36	Please address correspondence to:
37	Akl C. Fahed, MD, MPH
38	Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
39	E-mail: afahed@mgh.harvard.edu
40	
41 42	Minxian Wang, PhD
43	National Genomics Data Center, China National Center for Bioinformation, Beijing, China
44	E-mail: wangmx@big.ac.cn
45 46 47 48	Word count: 6414
49	
50	
51	
52	
53	
54	
55	
56	
57	

58 Abstract

59 Obesity and type 2 diabetes (T2D) are metabolic diseases with shared pathophysiology. Traditional polygenic risk scores (PRS) have focused on these conditions individually, yet the 60 61 single disease approach falls short in capturing the full dimension of metabolic dysfunction. We 62 derived biologically enriched metabolic PRS (MetPRS), a composite score that uses multi-63 ancestry genome-wide association studies of 22 metabolic traits from over 10 million people. 64 MetPRS, optimized to predict obesity (O-MetPRS) and T2D (D-MetPRS), was validated in the UK 65 Biobank (UKB, n=15,000), and tested in UKB hold-out set (n=49,377), then externally tested in 3 cohorts – All of Us (n=245,394), Mass General Brigham (MGB) Biobank (n=53,306), and a King 66 67 Faisal Specialist Hospital and Research Center cohort (n=6,416). O-MetPRS and D-MetPRS outperformed existing PRSs in predicting obesity and T2D across 6 ancestries (European, African, 68 East Asian, South Asian, Latino/admixed American, and Middle Eastern). O-MetPRS and D-69 70 MetPRS also predicted morbidities and downstream complications of obesity and T2D, as well as 71 the use of GLP-1 receptor agonists in contemporary practice. Among 37,329 MGB participants 72 free of T2D and obesity at baseline, those in the top decile of O-MetPRS had a 103% relatively higher chance, and those in the top decile of D-MetPRS had an 80% relatively higher chance of 73 74 receiving a GLP-1 receptor agonist prescription compared to individuals at the population median 75 of MetPRS. The biologically enriched MetPRS is poised to have an impact across all layers of clinical utility, from predicting morbidities to informing management decisions. 76

- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88

89 Introduction

90 Obesity and type 2 diabetes (T2D) are closely interconnected through a shared 91 pathophysiology, often characterized by insulin resistance, and together constitute a major portion 92 of metabolic diseases. This relationship, frequently referred to as "diabesity",¹ reflects the 93 overlapping genetic architecture of both conditions, emphasizing the need to study their combined 94 effects on metabolic health and related morbidities.^{2,3} While research into the shared and distinct 95 genetic bases of metabolic traits has provided valuable biological insights.⁴ this multivariable 96 knowledge has not been fully translated into clinical utility via genetic risk assessment. The 97 polygenic risk score (PRS) has emerged as a powerful tool for assessing composite genetic risks. 98 gaining traction for its potential clinical applications.^{5,6}

99 The PRSs for obesity and T2D have been developed individually based on a single 100 disease approach thus far,⁷ without accounting for the multivariable nature of these conditions. 101 We and others previously demonstrated that incorporating genetic information for relevant 102 diseases enabled a significant boost in disease risk predictive performance.^{8–10} Building on this 103 multi-disease approach, we have now further incorporated a broader spectrum of measures for 104 diabesity, acknowledging that different measures of obesity (e.g., body mass index[BMI], waist 105 circumference[WC], waist-to-hip ratio[WHR]) and diabetes (e.g., HbA1c, fasting glucose[FG], 106 insulin sensitivity) capture intersecting but also complementary biology of these conditions. For 107 instance, BMI typically measures overall body mass, whereas WC provides more specific 108 information about abdominal or central adiposity.¹¹ Leveraging multiple indices that measure 109 various dimensions of metabolic dysfunction may effectively capture the underlying metabolic 110 complexity and potentially translate it into a biologically enriched and clinically meaningful PRS.

111 By integrating genetic information for related diseases and measures, we developed a 112 metabolic PRS (MetPRS) optimized for obesity (O-MetPRS) and T2D (D-MetPRS). We 113 incorporated genetic data from 22 metabolic traits, utilizing multi-ancestry genome-wide 114 association study (GWAS) data from over 10 million participants. The model was validated and 115 tested in the UK Biobank (UKB), and externally tested in three multiethnic cohorts comprising up 116 to 300,000 participants. This multi-disease and multi-measure approach has resulted in a 117 biologically enriched and cross-ancestry transferable PRS capable of predicting a broad spectrum 118 of metabolic health outcomes with high accuracy and relevance to clinical care.

119 Results

120 We integrated GWAS summary statistics from 22 obesity and diabetes related traits 121 including, but not limited to, BMI, body weight, body fat percentage, WC, WHR, hip circumference, 122 abdominal subcutaneous adipose tissue (ASAT), visceral adipose tissue (VAT), gluteofemoral 123 adipose tissue (GFAT), HbA1c, fasting glucose, fasting insulin, 2-hr glucose, and insulin 124 sensitivity index (Supplementary Table 1). The GWAS summary statistics were derived from the 125 largest contemporary data consortia, including Million Veteran Program (MVP), FinnGen, Biobank 126 Japan (BBJ), UK Biobank (UKB), and Taiwan Biobank, encompassing over 10 million participants. 127 Participants in the UK Biobank were divided into three distinct groups: the dataset for GWAS, the

training set, and the hold-out test set, with no overlap between samples across these groups (Extended Data Fig.1). The obesity and T2D models were validated on 15,000 individuals of European ancestry, including 3,814 individuals with obesity (BMI \ge 30 Kg/m² for European) and 1,196 with T2D. UKB hold-out test set consisted of 49,377 individuals, with 70.1% of European ancestry, 13.9% of African ancestry, 2.6% of East Asian ancestry, and 13.4% of South Asian ancestry (Extended Data Fig.1 and Supplementary Table 2). The remaining European-ancestry samples (N=378,921) were used for *de novo* GWAS analysis, and incorporated in the PRS score

development (**Supplementary Table 1**). The model development process is illustrated in **Fig. 1**.

136 Genetic Correlations Among Metabolic Traits

137 We selected 22 traits associated with diabesity and insulin resistance for which GWAS 138 summary statistics are currently available and have no sample overlap with UK biobank participants 139 (Supplementary Table 1). We assessed the genetic correlations among 22 metabolic traits using 140 cross-trait LD-score regression (Fig. 2). Significant correlations were observed between traits 141 associated with obesity, such as BMI, WC, body weight, VAT, reflecting their shared genetic 142 underpinnings. For example, the genetic correlation between BMI and WC was 0.90, while VAT 143 showed strong correlations with both body fat (0.71) and WC (0.79), which remained significant 144 after multiple testing corrections (Fig. 2 and Supplementary Table 3). In contrast, the Modified 145 Stumvoll insulin sensitivity index (ISI)¹² displayed negative genetic correlations with most traits, 146 as the index is inversely related to insulin resistance.

147

148 Model Development and Internal Validation of MetPRS in the UK Biobank

149 We used a previously described multi-ancestry and multi-trait GWAS integration 150 framework⁸ for developing high-performance and cross-ancestry transferable metabolic PRS 151 (MetPRS), with the purpose specifically optimized to predict obesity (O-MetPRS) and T2D (D-152 MetPRS), Fig 1. The predictive performance of O-MetPRS and D-MetPRS was first evaluated in 153 the hold-out test set from the UK Biobank (n = 49,377) (Fig. 3 and Extended Data Fig.1). For 154 obesity among European participants, O-MetPRS achieved an odds ratio per standard deviation 155 (OR/SD) of 2.22 (95% CI: 2.16–2.28), outperforming all previously published PRSs for obesity – 156 the second best performing PRS for obesity (PGS catalog: PGS000027) had an OR/SD of 1.79 157 (95% CI: 1.75–1.84) (Fig. 3A and Supplementary Table 4). Moreover, the range of obesity 158 prevalence stratified by O-MetPRS was significantly broader, spanning from 2.9% to 70.3% 159 across percentiles, compared to 6.3% to 58.2% for the second best performing PRS, PGS000027 160 (Fig. 3B). For T2D, D-MetPRS showed an OR/SD of 2.08 (95% CI: 2.00–2.18), also exceeding 161 the performance of all previously published PRSs (Fig. 3C and Supplementary Table 5). 162 Similarly, D-MetPRS stratified a notably wider range of T2D prevalence, from 0.9% to 28.8% 163 across percentiles, compared to 2.6% to 23.9% for the second best PGS001357 (Fig. 3D). 164 Likewise, O-MetPRS and D-MetPRS consistently ranked as the top-performing PRSs for obesity 165 and T2D among African and East Asian participants (Fig. 3A and Fig. 3C). These findings 166 demonstrate that MetPRS provides superior risk stratification for both obesity and T2D in diverse 167 ethnic groups compared to existing PRSs.

168 We further tested the associations of O-MetPRS and D-MetPRS with various metabolic traits (Extended Data Fig.2 and Supplementary Table 6). A consistent significance across all 169 traits (P < 0.0001) suggested that both O-MetPRS and D-MetPRS effectively capture the genetic 170 171 predispositions related to obesity and T2D, respectively. O-MetPRS demonstrated large 172 association coefficients observed for weight (β = 4.75 Kg per SD, SE = 0.07, P < 0.0001), hip circumference (β = 2.95 cm per SD, SE = 0.047, P < 0.0001), and BMI (β = 1.86 Kg/m² per SD, 173 174 SE = 0.024, P < 0.0001), D-MetPRS showed strong associations with HbA1c (β = 1.434 mmol/mol 175 per SD, SE = 0.034, P < 0.0001), triglycerides (TG) (β = 6.53 mg/dl per SD, SE = 0.003, P < 176 0.0001), and glucose (β = 3.098 mg/dl per SD, SE = 0.007, P < 0.0001). Notably, O-MetPRS has 177 a larger effect size on obesity-related traits and D-MetPRS has larger effect size on diabetes-178 related traits, suggesting that each score captured its relevant biological insights.

179 External validation of MetPRS in multiple cohorts

180 We validated the MetPRS in three external multiethnic cohorts: All of Us (n = 245,394), 181 Mass General Brigham (MGB) Biobank (n = 53,306), and the King Faisal Specialist Hospital and Research Center [KFSH&RC] cohort (n = 6,416) (Fig. 4; Supplementary Tables 7-12). MetPRS 182 183 was compared against the top 5 obesity and T2D PRSs from the PGS Catalog.¹³ We selected the 184 top 5 PRSs that consistently ranked highly across all external datasets as comparators, excluding 185 any scores that incorporated each test cohort (i.e., All of Us) in their score development. The OR/SD with 95% CI for prevalent obesity and T2D was assessed for O-MetPRS and D-MetPRS. 186 187 respectively, in a logistic regression model adjusted for age, sex, genotyping array, and the first 188 10 principal components of ancestry. MetPRS was the best-performing score across diverse 189 ancestries, except for O-MetPRS in the East/South Asian population of MGB Biobank, D-MetPRS 190 in Middle Eastern population of All of Us, and D-MetPRS in East Asian population of MGB Biobank 191 (Fig.4). In addition to predicting binary obesity, we also evaluated O-MetPRS for its ability to 192 predict continuous BMI (Extended Data Fig.3). O-MetPRS outperformed the top five comparator 193 scores across diverse ancestries in predicting BMI, with the exception of East/South Asian and 194 African populations in the MGB Biobank (Extended Data Fig.3 and Supplementary Table 13). 195 The consistently high performance across multi-ancestry external cohorts underscored the 196 robustness and generalizability of MetPRS.

197 Although MetPRS consistently performed better than pre-existing scores across 198 ancestries in relative space, its performance was suboptimal in individuals of African ancestry 199 (**Fig. 4**). To address this gap, we developed an African-optimized MetPRS by training the model 200 in UK Biobank African participants, which led to a further performance improvement tested in the 201 All of Us and MGB Biobank (**Extended Data Fig.4**).

202 Prediction of Morbidities Related to Obesity and Type 2 Diabetes

203 Obesity and T2D are not only major health challenges on their own but also serve as 204 strong risk factors and precursors for a wide array of downstream diseases and complications. 205 We assessed the ability of MetPRS to predict morbidities related to obesity and T2D using a Cox 206 proportional hazards model for individuals in the MetPRS top decile compared to those of the rest

207 cohort; the risk of all tested morbidities was significantly higher in top decile group for O-MetPRS and D-MetPRS (Extended Data fig.5; Supplementary Table 14). When compared to the top 5 208 209 comparator scores, O-MetPRS had the best prediction of obesity-related morbidities, ranking first 210 for predicting 12 out of 14 obesity-related morbidities such as hypertension (hazard ratio[HR] 1.39; 211 95% CI: 1.30-1.49), venous thromboembolism (HR1.47; 95% CI: 1.21-1.80), and Nonalcoholic 212 fatty liver disease (HR 1.83; 95% CI: 1.41-2.37) (Fig. 5A and 5B; Extended Data Fig. 6). Similarly, 213 D-MetPRS most accurately predicted diabetes-related morbidities, ranking first for predicting 11 214 out of 13 diabetes-related morbidities such as neuropathy (HR 1.87; 95% CI: 1.35-2.59), 215 nephropathy (HR 1.89; 95% CI: 1.65-2.16), and retinopathy (HR 1.87; 95% CI: 1.35-2.59) (Fig. 216 5C and 5D; Extended Data Fig. 6).

217 MetPRS and Risk of GLP-1 Receptor Agonist Prescription and Metabolic-bariatric Surgery

218 The MGB Biobank consisted of 51,779 eligible participants, of whom 4,490 (8.7%) were 219 prescribed GLP-1 receptor agonists during a mean follow-up of 5.53 (SD 2.96) years, and 1,487 220 (2.9%) underwent metabolic-bariatric surgery during a mean follow-up of 5.53 (SD 3.32) years. 221 Among 51,779 participants, 37,329 were free of obesity and T2D at baseline. To evaluate the 222 relationship between MetPRS and clinical interventions in contemporary practice, we employed 223 Cox proportional hazards regression models, adjusting for age, sex, and top 10 ancestry principal 224 components. Participants were categorized into three risk groups based on their MetPRS - the 225 top 10%, middle quintile (40–60%), and bottom 10%.

226 Among 37,329 MGB individuals free of obesity and T2D, those in the top decile compared 227 to the population median quintile of O-MetPRS had a markedly increased risk of receiving a GLP-228 1 agonist prescription (HR 2.03; 95% CI: 1.65-2.50) and metabolic-bariatric surgery (HR 3.61; 95% 229 CI: 2.06-6.33). The cumulative incidence of GLP-1 receptor agonist prescriptions and metabolic-230 bariatric surgery showed significant variation across different O-MetPRS risk groups at 10-year 231 (Fig. 6A and 6B; Extended Data Fig. 7A and 7B). Among the group free of obesity and T2D at 232 baseline, participants in the top 10% risk group had a cumulative incidence of 12.6% for GLP-1 233 receptor agonist prescriptions and 0.4% for metabolic-bariatric surgery. For the middle quintile 234 group, the cumulative incidences were 6.5% and 0.1%, while the bottom 10% group had 235 incidences of 3.4% and 0.0%, respectively (Fig.6A and 6B). These trends were consistent in the 236 overall population, which included some participants with obesity and T2D at baseline who had 237 not been treated with these interventions. The cumulative incidence of GLP-1 receptor agonist 238 prescriptions and metabolic-bariatric surgery was generally higher in this population (Extended 239 Data Fig. 7A and 7B).

240 Similarly, those in the top decile compared to the population median guintile of D-MetPRS 241 had a substantially increased risk of receiving a GLP-1 agonist prescription (HR 1.80; 95% CI: 242 1.47-2.21) and metabolic-bariatric surgery (HR 2.29; 95% CI: 1.29-4.06). The cumulative 243 incidence of GLP-1 receptor agonist prescriptions and metabolic-bariatric surgery also varied 244 notably across the D-MetPRS risk groups at the 10-year mark (Fig. 6C and 6D; Extended Data 245 Fig. 7). In the population, those in the top 10% risk category had cumulative incidences of 12.1% 246 for GLP-1 receptor agonist prescriptions and 0.4% for metabolic-bariatric surgery. In contrast, the 247 middle quintile group had cumulative incidences of 7.0% and 0.2%, and the bottom 10% group

had 3.9% and 0.0%, respectively (Fig.6C and 6D). These patterns persisted in the overall
population with higher incidence rates (Extended Data Fig. 7C and 7D).

250

251 Discussion

252 This study introduces MetPRS for diabesity based on a novel approach that captures the 253 genetic architecture of metabolic dysfunction by synthesizing genetic association data from 254 related measures and indices. This method leveraged biological insights to optimize genetic risk 255 prediction for obesity, T2D, their related morbidities, and even clinical interventions in 256 contemporary practice. We demonstrate that MetPRS outperformed all previous PRSs in 257 predicting obesity and T2D across multiple ancestries, including European, African, East Asian, 258 South Asian, Latino/admixed American, and Arab populations. Moreover, MetPRS precisely 259 predicted downstream morbidities and clinical interventions associated with diabesity, such as 260 GLP-1 receptor agonist prescriptions and metabolic-bariatric surgery, underscoring its potential 261 clinical utility. The biologically enriched MetPRS is well-positioned to penetrate various aspects 262 of clinical practice, from predicting morbidities to guiding management decisions.

263 Metabolic disorders are inherently multifactorial and involve complex biology. As such, 264 integrating GWAS data for various diabesity-related measures resulted in a biologically-enriched 265 PRS. No single metric can fully capture the etiology of metabolic disorders, necessitating the 266 complementary use of multiple measures in clinical practice. For instance, HbA1c and fasting 267 glucose levels offer complementary insights - HbA1c reflects long-term glycemic control, while 268 fasting glucose levels indicate immediate glucose control.¹⁴ Likewise, multiple obesity measures, 269 such as BMI, WC, WHR, VAT, ASAT, and GFAT provide both converging and diverging insights 270 into different obesity subtypes and risk trajectories for obesity related morbidities.¹⁵ This growing 271 body of evidence supported our strategy to develop a biologically-enriched PRS by leveraging 272 genetic information across multiple diabesity-related measures. Emdin et al. previously 273 demonstrated that a PRS for WHR adjusted for BMI (WHRadjBMI) could capture a genetic 274 predisposition to adiposity that was not evident when using the genetic risk of WHR or BMI 275 alone.¹⁶ Meanwhile, their study was limited to combining only two metrics and was not specifically aimed at developing PRS that captures whole dimensions of underlying etiologies. We integrated 276 277 a wider range of measures (22 measures), creating a metabolic PRS that is more comprehensive 278 and better equipped to reflect the complex and heterogeneous nature of metabolic disease 279 manifested by obesity and T2D.

280 O-MetPRS and D-MetPRS demonstrated superior predictive accuracy compared to 281 previously developed PRSs for obesity and T2D in the PGS catalog in both internal and external 282 validations (Fig. 3 and 4). The genome-wide PRS for obesity (GPS_{BM}) introduced by Khera et 283 al.(PGS000027),⁷ which utilized 2.1 million genetic variants, had previously set the benchmark for 284 obesity PRS performance. However, our O-MetPRS showed a significant improvement, with an 285 over 20% increase in OR/SD compared to GPS_{BMI} (GPS_{BMI} OR/SD 1.79 vs. O-MetPRS OR/SD 286 2.22 in European population) (Fig. 3). This substantial enhancement could be attributed to the 287 difference in genetic inputs and reflecting their biological relevance (Extended Data Fig.8); O-288 MetPRS incorporated multiple ancestry GWAS from 22 traits, whereas GPS_{BM} relied on only BMI 289 and European GWAS data. Similarly, D-MetPRS demonstrated over 20% increase in OR/SD 290 compared to the second highest T2D PRS—AnnoPred PRS (PGS001357) (AnnoPred OR/SD

1.69 vs. O-MetPRS OR/SD 2.08 in European population).¹⁷ Such improvement over previous top
 scores for both obesity and T2D underscores the value of our multiplicative approach.

293 Obesity and T2D are not only major health concerns in their own right but also strong risk factors for numerous morbidities,¹⁸⁻²² making it important to predict their related comorbidities for 294 295 better health management. Our study demonstrates that MetPRS had a substantial improvement 296 in predicting downstream morbidities and complications of diabesity compared to existing PRSs 297 (Fig. 5 and Extended Data Fig.6), likely due to its biologically enriched composition. Moreover, 298 MetPRS effectively predicted cardiovascular mortality, likely indicating its ability to identify 299 individuals at risk for poorer outcomes or prognosis, beyond merely predicting disease incidence. 300 Few AI-based tools and clinical scores have been developed to predict obesity-related or diabetic 301 complications, yet they require clinical factors that usually become evident in middle age as 302 inputs.^{23–25} In contrast, MetPRS can predict morbidities long before the clinical factors manifest, 303 potentially as early as birth.⁷ As sequencing technologies advance and become more cost-304 effective and affordable,^{26,27} the use of MetPRS can shift morbidity care earlier in life and support 305 primordial prevention.

306 The MetPRS was able to predict the likelihood of requiring GLP-1 receptor agonist 307 prescription in a population free of obesity and T2D at baseline, over a period of following up to 308 13 years. The GLP-1 receptor agonists are indicated for treating obesity and T2D, yet their 309 indications are expanding as mounting evidence shows their efficacy in reducing cardiovascular 310 diseases,²⁸ steatohepatitis,²⁹ chronic kidney disease,³⁰ and other conditions.^{31,32} Despite its 311 growing status as a widely used treatment, the challenges in the pharmacological intervention lie 312 in evaluating the risk-benefit ratio for each individual, as GLP-1 receptor agonists are not without 313 adverse effects.^{33,34} An even greater concern is the significant economic burden these 314 medications impose on healthcare systems, particularly in countries like the US, where up to 40% of the population may be eligible for treatment.^{35,36} Therefore, the ability to extend genetic 315 316 prediction to GLP-1 receptor agonist prescription holds clinical implications, adding a data point 317 for risk-benefit assessment, patient-physician communication, and cost-effective rollout. Currently, 318 GLP-1 receptor agonists are typically reserved for individuals with obesity or diabetes who have 319 comorbidities or have not achieved sufficient control through lifestyle modifications.^{37,38} The ability 320 to genetically predict the eventual need for this drug could potentially move the needle in 321 management plans and health system strategies.

322 MetPRS is a multi-ancestry PRS that can be readily applied to diverse populations, as it 323 showed robust prediction performance across different ancestries in our external validation data 324 sets (Fig. 4). The Eurocentric bias inherent in many genetic studies has significantly limited the 325 generalizability of PRSs, presenting a major barrier to their implementation in real-world settings 326 where populations are inherently diverse.³⁹⁻⁴² Our study addressed this challenge by 327 incorporating GWAS data from multiple ancestries when developing the model, ensuring that 328 genetic information from non-European populations is represented. We then validated the 329 MetPRS across multiple ancestries, demonstrating consistent best performances across these 330 populations. Notably, even though some existing PRSs were optimized for their specific non-331 European ancestries, our multi-ancestry MetPRS still outperformed them in respective non-

European populations (**Fig. 3 and Fig. 4**). Given its reliable performance among various ancestries, MetPRS can be readily implemented in ethnically diverse settings and contexts. Our findings contribute to the growing body of evidence that multi-ancestry genetic studies can facilitate more inclusive and widely applicable health services and alleviate the risk of propagating potential healthcare disparities in genomic medicine.^{8,43}

337 There are several limitations that must be acknowledged. First, while we incorporated 338 multi-ancestry and non-European GWAS data to train MetPRS, the majority of the data used for 339 model development and validation is still derived from GWAS of European descent, which may 340 affect the score's performance in non-European populations. Reassuringly, MetPRS consistently 341 performed better than pre-existing scores across ancestries on a relative scale. However, its 342 performance was suboptimal in individuals of African ancestry, and thus we developed an African-343 optimized MetPRS, which led to a modest improvement in performance. Second, our study 344 centered on obesity and T2D among metabolic traits. Future research could explore the inclusion 345 of additional metabolic traits or different combinations based on biological commonality. However, there are several justifications for our focus. We specifically targeted obesity and T2D due to their 346 347 closely related pathophysiology^{1,2} and shared treatment options, including GLP-1 receptor agonists and metabolic-bariatric surgery.44-46 Convergence in clinical management was a 348 349 particularly important consideration, as our aim for MetPRS was to design a PRS that can predict 350 across various layers of clinical aspects. The intersecting foundation in biology, etiology, and 351 clinical workflow pertinent to both conditions enabled MetPRS to be a clinically relevant PRS. 352 Finally, the clinical implementation of MetPRS requires further consideration of how to interpret 353 and communicate PRS results to healthcare providers and patients, as well as how to measure 354 its impact on patient outcomes and healthcare decision-making.⁴⁷

355 Conclusion

356 This study presented a novel approach to genetic risk prediction of diabesity by introducing 357 the MetPRS, a composite metabolic PRS that integrates multi-ancestry, multi-disease, and multi-358 measure genetic data. Our findings have significant implications for precision medicine, offering 359 more comprehensive scores to predict risks for obesity and T2D, as well as their complications 360 and clinical management. The MetPRS outperformed traditional single-trait PRS models, 361 demonstrating the value of a biologically-enriched approach to genetic risk prediction. By 362 leveraging multi-ancestry GWAS data, MetPRS represents a step forward in creating more 363 equitable and inclusive tools for genomic medicine.

- 364
- 365
- 366
- 367

368 Methods

369 Study cohorts

370 UK Biobank

371 The UK Biobank (UKB) is an observational study that enrolled over 500,000 individuals 372 aged 40 to 69 across the United Kingdom between 2006 and 2010. At the time of recruitment, 373 participants provided electronically-signed consent, completed questionnaires on socio-374 lifestyle, and health-related factors, and underwent various physical demographic. 375 assessments.⁴⁸ Anthropometric measurements, including body mass index, were measured at 376 the initial enrollment visit. Among participants, 43,521 underwent MRI imaging between 2014 and 377 2020.^{49,50} Participants were genotyped using the UK BiLEVE Axiom Array or the UK Biobank 378 Axiom Array, each containing over 800,000 genome-wide variants. Imputation was carried out using reference panel from the Haplotype Reference Consortium (HRC),⁵¹ UK10K,⁵² and the 1000 379 380 Genome Phase 3 data.⁵³ The HRC was used as the primary imputation reference panel due to 381 its large sample size (64,976 broadly European haplotypes). The 1000 Genomes phase 3 dataset 382 was employed to assist with the phasing of samples from non-European ancestries. Imputation 383 results were also combined from the merged UK10K and 1000 Genomes phase 3 reference 384 panels and the HRC panel, with HRC imputation being prioritized when a SNP was present in 385 both panels. Imputation was conducted using IMPUTE 4 (https://jmarchini.org/software/).

386387 All of Us

388 The All of Us (AoU) Research Program is a longitudinal cohort study that has enrolled a 389 diverse group of traditionally underrepresented individuals aged 18 and older from more than 730 sites across the United States.⁵⁴ Since its inception in 2018, the AoU program has consented to 390 391 over 800,000 participants, with more than 560,000 completing the initial enrollment process, 392 including health questionnaires and biospecimen collection. For these participants, ongoing 393 linkage to electronic health record (EHR) data, including International Classification of Diseases 394 (ICD)-9/ICD-10, Systematized Nomenclature of Medicine (SNOMED), and Current Procedural 395 Terminology (CPT) codes, is maintained. This study utilized whole-genome sequencing (WGS) 396 data from over 245,000 participants available in the Controlled Tier Dataset, version 7 release. 397 Data analysis was conducted on the All of Us Researcher Workbench under the guidelines 398 defined by the All of Us Ethical Conduct of Research Policy.

399

400 Mass General Brigham Biobank

The Mass General Brigham Biobank (MGBB) is a large-scale, healthcare-affiliated biobank based in the Greater Boston area of Massachusetts.^{55,56} Established in 2010, the MGBB has enrolled approximately 140,000 diverse individuals within the Mass General Brigham (MGBB) network, the largest healthcare system in Massachusetts. The biobank aims to uncover the complex relationships among genomic profiles, environmental factors, and disease manifestations in clinical practice. MGBB provides biomedical samples, such as plasma, serum, DNA, buffy coats, collected from patients and linked to clinical data from the EHR, quantitative

data derived from medical images, and survey data on lifestyle, environment, and family history.⁵⁷
 Genome-wide genotyping arrays of 53,306 MGBB participants were used in this study.

410

411 King Faisal Specialist Hospital and Research Center cohort

The King Faisal Specialist Hospital and Research Center (KFSH&RC) cohort consists of indigenous Arabs from Saudi Arabia referred for cardiology care at KFSH&RC, a tertiary care hospital recognized throughout Saudi Arabia and the Middle East, for work-up of cardiac disease from all over the country⁵⁸. In addition to blood samples for DNA extraction and genotyping array analyses, participants provided access to their electronic health records for phenotype data and shared socio-demographic information through a clinical research coordinator. All participants gave informed consent to participate in the study.

419

420 Phenotype definitions

421

422 For the UK Biobank participants, weight and height were collected at baseline when 423 participants attended the initial assessment center. BMI was constructed from height and weight 424 measured during the initial Assessment Centre visit. BMI is not present if either of these readings 425 were omitted. Obesity was defined as a BMI \ge 25 kg/m² for individuals of East Asian ancestry and 426 a BMI ≥ 30 kg/m² for individuals of other ancestries, ^{59,60} which was used also for AoU, MGBB and 427 KFSH&RC cohorts. T2D was identified either through self-reported diagnosis during an interview 428 with a trained nurse or via the ICD-10 code E11.X in hospitalization records. For comorbidities, 429 detailed definitions of diseases included in the comorbidities analysis are provided in 430 **Supplementary Table 17.** For example, coronary artery disease cases were defined centrally 431 based on self-report at enrollment, hospitalization records, or death registry records; retinopathy 432 case ascertainment was based on hospitalization records and death registry records; sleep apnea 433 ascertainment was based on self-report at the time of enrollment, hospitalization records, and 434 death registry records.

435 For All of Us, BMI was taken from physical measurements of EHR data. T2D was identified 436 as EHR records containing the term "Type 2 diabetes mellitus" in Controlled Tier Dataset v7 437 Conditions. For MGBB, BMI was obtained from the electronic health records T2D was identified 438 as glycated hemoglobin \geq 6.5% or diagnosis records from the electronic health records. For 439 the KFSH&RC cohort, disease status and metabolic traits were collected during routine clinical 440 care and manually extracted from the electronic health record by trained medical personnel. The 441 diagnosis of T2D was curated from the electronic health records. Height and weight 442 measurements obtained in the context of care and the first visit measured on referral to the King 443 Faisal Specialist Hospital and Research Center was used.

444

445 Define polygenic risk score percentiles

446

Residual scores for MetPRS, and PRS scores calculated by the variant weight from the
 PGS Catalog were extracted after adjustment for the first ten principal components of genetic
 ancestry, then normalized to a mean of 0 with a standard deviation of 1. The percentile distribution

450 of the polygenic risk scores was analyzed to assess the stratification of obesity (BMI \ge 30 kg/m²) 451 and T2D.

452

453 **Quality control and sample selection**

454

455 UK Biobank

Participants were excluded from the analysis if they met any of the following criteria: (1) a mismatch between self-reported sex and genetically inferred sex, (2) sex chromosome aneuploidy, (3) a genotyping call rate below 0.95, (4) being outliers for heterozygosity, (5) having seconddegree or closer relatives, (6) with unknown self-reported ancestry, or (7) without BMI or T2D phenotypes. After applying these sample quality controls, 444,345 participants remained available (**Extended Data Fig.1**).

462 To further boost the power for constructing PRS scores, we conducted de novo GWAS for 463 ten traits (BMI, T2D, body fat percentage, height, body weight, waist circumference, hip 464 circumference, HbA1c, Glucose, cT1) traits utilizing data from 378,921 participants randomly 465 selected from UKB European ancestry participants (self-reported ancestry, Field ID 21000). For 466 the remaining participants of European ancestry, 15,000 and 34,626 individuals were assigned to 467 the training and testing sets for PRS score development, respectively. A total of 1,304 individuals 468 who self-identified as Chinese were included for East Asian ancestry validation, 6,842 individuals 469 who self-identified as Black were included for African ancestry validation, and 6,605 individuals 470 of South Asian descent (self-reported as Indian, Pakistani, or Bangladeshi) were included for 471 South Asian ancestry validation. Individuals with body (abdominal) magnetic resonance imaging 472 (MRI) data (UK Biobank Field ID 12224) were excluded from the training and validation datasets, 473 since GWAS for MRI-derived visceral (VAT), abdominal subcutaneous (ASAT), and gluteofemoral 474 (GFAT) adipose tissue volumes was conducted on UKB MRI-tested participants;⁶¹ we additionally 475 excluded individuals with whole body DXA scan (UK Biobank Field ID 20201), (Extended Data 476 Fig.1).

Genetic variants were included in the GWAS if they met the following quality control criteria: (1) imputation quality score (INFO) > 0.3, (2) minor allele frequency (MAF) > 0.001, (3) minor allele count (MAC) > 100, and (4) SNP genotyping missing rate < 10%. These criteria resulted in a total of 15,848,715 imputed variants available for analysis. Common variant association studies for ten traits (BMI, T2D, body fat percentage, height, body weight, waist circumference, hip circumference, HbA1c, Glucose, cT1) were conducted using REGENIE (v3.2.7), genotype variants were centrally imputed from UK Biobank.⁴⁸

- 484
- 485 All of Us

486 Within All of Us, details of whole genome sequencing and quality control are described 487 extensively in Jurgens et al.⁶² and the All of Us Genomic Research Data Quality Report 488 C2022Q4R9 CDR v7, available at https://support.researchallofus.org/hc/enus/articles/4617899955092-All-of-Us-Genomic-Quality-Report. Briefly, 229,517 out of total 489 490 245,394 samples remained after filtering for sex concordance, a cross individual contamination 491 rate below 3%, a call rate above 98% and related samples by AoU Central quality control. We 492 used the Allele Count/Allele Frequency (ACAF) threshold SNP callset curated by AoU, which

includes SNPs of population-specific allele frequency > 1% or allele counts over 100 for each ancestral subpopulation. The inferred ancestry information is obtained from the "ancestry_pred" column, which is available as part of the genetically predicted ancestry TSV file. The quality control metrics were centrally provided by the AoU project.⁵⁴ SNPs deviated from Hardy-Weinberg equilibrium (P < 1×10^{-6}) in each genetic ancestry were removed. Principal components of genetic ancestry used for the correction of population structure were calculated in each ancestry group separately using SNPs present in the 1000 Genomes project phase 3 release.

500

501 Mass General Brigham Biobank

502 Within MGB Biobank, 53,306 individuals were genotyped by Illumina Global Screening 503 Array (Illumina, CA) and imputed to the TOPMed multi-ancestry imputation reference panel 504 (TOPMed r2 panel).⁵⁶ Variants with high missingness (> 2%) and low MAF (< 1%) and variants 505 that failed the Hardy–Weinberg test ($P < 1 \times 10^{-6}$) were removed. After excluding individuals due 506 to discrepancies between reported and genotypic sex, sex chromosome aneuploidy, genotyping 507 call rate < 0.95, heterozygosity outliers, and excess relatedness (second-degree relatives or 508 closer), 49,825 individuals remained for validation. We inferred genetic ancestry using a public 509 diverse population, including 3,380 unrelated individuals from the 1000 Genomes Project (1KG) 510 and the Human Genome Diversity Project (HGDP), called 1KG HGDP.⁶³ We extracted common, 511 high-quality SNPs (missingness < 1%, MAF > 1%) across MGBB and the 1KG_HGDP dataset. 512 After pruning SNPs, we computed SNP weights for the genetic principal component using the 513 1KG HGDP dataset. Then, we projected MGBB participants into the same principal component 514 space using the top 20 PCs. Using genetic PCs in the 1KG_HGDP dataset as a feature matrix, 515 we trained a K-nearest neighbor model (k=1) for 1KG HGDP reference populations to assign 516 population labels to MGBB participants.

517

518 King Faisal Specialist Hospital and Research Center cohort

All participants from the King Faisal Specialist Hospital and Research Center cohort were of Middle Eastern ancestry and variants and sample quality control were previously described.⁵⁸ Briefly, we excluded samples due to variant calling missingness > 5%, heterozygosity rate > 5 standard deviations above the mean, and mismatch between genotypically-determined and selfreported sex. Variant-level quality control was conducted to remove variants with call rate < 98%, MAF < 0.01, or Hardy–Weinberg test ($P < 1 \times 10^{-6}$). After imputation by TOPMed r2 panel datasets, the variants with INFO < 0.3 and MAF < 0.01 were removed.

526

527 Genetic correlation estimation between traits

528

529 We selected 22 traits that directly or indirectly serve as proxies for the status of obesity 530 and T2D (**Supplementary Table 1**). Our focus on obesity and T2D among various metabolic 531 diseases is due to their closely related pathophysiology and shared treatment options, including 532 GLP-1 receptor agonists and metabolic-bariatric surgery. This common biological, etiological, and 533 clinical foundation justified the development of a composite metabolic PRS for diabesity. We 534 defined a 'trait' as a composite of binary disease status (e.g., T2D) and continuous measures for 535 metabolic status (e.g., BMI, HbA1c).

536 Genetic correlations between 22 traits were estimated using cross-trait LD-score 537 regression (LDSC v1.0.1). Precomputed LD scores were obtained from ~1.2 million common 538 SNVs in the well-imputed HapMap3 variants panel.⁶⁴ For each trait, only GWAS with the largest 539 sample size of European individuals was used to perform cross-trait LD-score regression analysis. 540 A Bonferroni corrected P value threshold of 0.00227 (0.05/22) was used to define statistical 541 significance.

542

544

543 **Polygenic risk score derivation**

545 Summary statistics from recent obesity and T2D-related GWAS studies (**Supplementary** 546 **Table 1**) conducted in diverse ancestries were used to determine the primary weights for obesity 547 and T2D PRSs. To ensure an independent holdout dataset for training and validating the obesity 548 and T2D metabolic polygenic risk scores (O-MetPRS and D-MetPRS), UK Biobank participants 549 for de novo GWAS were excluded for PRS score development (**Extended Data Fig.1**). Ancestry-550 specific linkage disequilibrium (LD) reference panels were derived from the 1000 Genomes 551 Project phase 3 data to match the ancestry of the discovery GWAS.

552 The construction of O-MetPRS and D-MetPRS involved a two-layer process (**Fig.1B**). In 553 layer 1, multiple PRS derived from ancestry-specific GWAS data were combined to yield a multi-554 ancestry PRS for each trait. In layer 2, the multi-ancestry PRSs for 22 traits were further combined 555 to generate MetPRS.

In layer 1, separate PRSs were constructed based on each ancestry-stratified GWAS using the LDpred2 method, a Bayesian approach that calculates posterior mean effects for all variants, considering prior GWAS effect sizes and subsequent shrinkage based on LD.⁶⁵ Only HapMap3 variants—a set of 1,296,172 variants representing common genetic variation across diverse populations—were included in the score calculation.

561 The LDpred2 method used default parameters, including proportion of causal variant (values of P = 1.0×10^{-4} , 1.8×10^{-4} , 3.2×10^{-4} , 5.6×10^{-4} , 1.0×10^{-3} , 1.8×10^{-3} , 3.2×10^{-3} , 5.6×10^{-4} , 1.0×10^{-3} , 1.8×10^{-3} , 3.2×10^{-3} , 5.6×10^{-4} , 1.0×10^{-3} , $1.8 \times$ 562 × 10⁻³, 1.0 × 10⁻², 1.8 × 10⁻², 3.2 × 10⁻², 5.6 × 10⁻², 1.0 × 10⁻¹, 1.8 × 10⁻¹, 3.2 × 10⁻¹, 5.6 × 10⁻¹ 563 564 and 1), heritability scales (s = 0.7, 1, and 1.4), and whether a sparse LD matrix was applied. 565 These parameter combinations yielded 102 candidate PRSs for each GWAS summary statistic. 566 Genotypes were extracted from a centrally imputed data repository by the UK Biobank, processed using bgenix,⁶⁶ and PRSs were calculated for each individual in the UK Biobank using PLINK 567 568 2.0.67 The best PRS was selected based on its performance in predicting obesity or T2D in an 569 independent sample of 15,000 White British individuals from UK Biobank. The obesity model used 570 log(BMI) as the outcome, while the diabetes model used T2D. The best score for each ancestry 571 was selected based on predictive performance measured by odds ratio (binary traits) or 572 incremental R²(continuous traits). The discriminative capacities (AIC) were then used to 573 determine the optimal combination of different ancestry scores. A regression model estimated the 574 mixing weights for ancestry-specific PRSs, which were then linearly combined into a single multiancestry score. Similar procedures were followed for other diabesity-related traits. 575

576 In layer 2, these multi-ancestry trait-specific PRSs were linearly combined with the multi-577 ancestry obesity/T2D PRSs from layer 1 to generate the final O-MetPRS and D-MetPRS. Same 578 as the layer 1, stepAIC was used for the feature selection for predicting log(BMI) or T2D to identify

579 the best combination of trait-level scores for mixing. Then, a regression model was used to 580 estimate the mixing weights for each individual trait-specific PRS as described above, which were 581 then linearly combined into a single MetPRS (O-MetPRS or D-MetPRS). Among the 93 ancestry-582 and trait-specific scores analyzed in the MetPRS training, 31 and 37 scores significantly 583 contributed to the overall prediction in O-MetPRS and D-MetPRS, respectively, after optimization 584 with stepAIC and weighting via regressions across both layers. The final mixing weights for each 585 layer were summarized in Extended Data fig 8, and were listed in Supplementary Table 15 and 586 **16**.

587

588 **Polygenic risk score validation**

589

590 MetPRS underwent internal hold-out validation within UK Biobank. To evaluate its 591 performance, we compared it with previously published polygenic risk scores for BMI and T2D 592 from the PGS Catalog (https://www.pgscatalog.org/). The variant effect sizes for these scores 593 were obtained from the PGS Catalog and calculated within the same UK Biobank testing dataset. 594 which included 34,626 European ancestry samples, 6,842 of African ancestry, 1,304 of East Asian 595 ancestry, and 6,605 South Asian ancestry samples (Extended Data Fig.1). External validation 596 was also performed in the All of Us (n=245,394), MGB Biobank (n=53,306), and a KFSH&RC 597 cohort (n=6,416).

598

599 GLP-1 agonist prescription and metabolic-bariatric surgery

600

601 We conducted a comprehensive analysis using data from the MGB Biobank to evaluate 602 the predictive utility of MetPRS for incident GLP-1 receptor agonist prescriptions and metabolic-603 bariatric surgeries. GLP-1 receptor agonist prescription and metabolic-bariatric surgery were 604 selected as clinical endpoints as they are interventions indicated for obesity and/or T2D. Initial 605 datasets were filtered to include only individuals with complete genotypic and phenotypic data. 606 excluding those censored before the biobank enrollment date, leaving 51,779 participants for 607 analysis. For each participant, O-MetPRS and D-MetPRS were calculated using ancestry-608 adjusted models. The first ten principal components were regressed out of the raw O-MetPRS 609 and D-MetPRS using linear regression to account for population stratification. The residuals from 610 this regression, which represent the MetPRS adjusted for ancestry, were then standardized to 611 have a mean of 0 and a standard deviation of 1.

612 To assess the association of MetPRS with clinical interventions, we utilized Cox 613 proportional hazards regression models adjusted for age, sex, and ancestry PCs. We stratified 614 participants into three risk groups based on their MetPRS values: top 10%, middle quintile (40-615 60%), and bottom 10%. The primary outcomes were the cumulative incidence of GLP-1 receptor 616 agonist prescriptions and metabolic-bariatric surgery over the follow-up period. Incidence was 617 tracked from baseline until the first event or censoring. Competing risk models were applied to 618 calculate cumulative incidence functions, and Kaplan-Meier curves were generated to visualize 619 time-to-event data.

620

621 Statistical analysis

622 For score training and validations, prediction for a continuous trait was calculated using 623 linear regression models, while logistic regression models were employed for predicting the risk 624 of a binary trait. All the models included baseline covariates: enrollment age, sex, genotyping 625 array, and the first ten principal components of genetic ancestry. For the comorbidities analysis, 626 the top decile of the PRS distribution was labeled as "carriers," while the remaining individuals 627 were labeled as "non-carriers". The top five obesity and T2D scores in the score comparisons 628 among 34.626 European individuals from the UK Biobank were compared with the O-MetPRS 629 and D-MetPRS, respectively. Cox proportional-hazards models were used to estimate hazard 630 ratios (HRs) for incident diseases in the UK Biobank, with enrollment age, genetically inferred sex, 631 genotyping array, and the first ten principal components as covariates. The frequency of the 632 highest prediction for each score was then calculated. All statistical analyses were performed 633 using R software (version 4.2.2, R Project for Statistical Computing), and figures were generated 634 using the ggplot2 R package (version 3.4.2).

635

637

636 Data availability

638 All data are made available from the UK Biobank (https://www. ukbiobank.ac.uk/enable-639 your-research/apply-for-access) to researchers from universities and other institutions with 640 genuine research inquiries following institutional review board and UK Biobank approval. This 641 research was conducted using the UK Biobank resource under application number 89885. All of 642 Us data are made available from the All of Us Research Study to researchers from universities 643 and other institutions with genuine research inquiries following institutional review board and All 644 of Us approval. KFSH&RC and MGBB data are governed by local laws, so relevant data could be 645 made available by contacting the investigators. The genome-wide association data supporting the 646 findings of this study are publicly available in KoGES (https://koges.leelabsg.org/), Biobank Japan 647 (http://jenger.riken.jp/en/result), FinnGen (https://www.finngen.fi/en/access results), AGEN T2D 648 (https://kp4cd.org/index.php/node/309), GIANT 649 (https://portals.broadinstitute.org/collaboration/giant/) and Million Veteran Program (via dbGaP at

- https://ftp.ncbi.nlm.nih.gov/dbgap/studies/, under accession number phs001672). The research
 was approved by the Beijing Institute of Genomics (Chinese Academy of Sciences) and the China
 National Center for Bioinformation institutional review board, and the Mass General Brigham
 institutional review board.
- 654 655 Acknowledgments
- 656

657 P.N. is supported by grants from the National Institutes of Health (R01HL127564, U01HG011719), 658 P.T.E. is supported by grants from the National Institutes of Health (1R01HL092577, 659 1R01HL157635, 5R01HL139731), from the American Heart Association Strategically Focused 660 Research Networks (18SFRN34110082), and from the European Union (MAESTRIA 965286). P.N. is supported by grant from National Human Genome Research Institute (U01HG011719). 661 662 A.C.F. is supported by grants from the National Heart Lung and Blood Institute (K08HL161448 663 and R01HL164629). Dr. Wang is supported by the Pioneering Action Grants of the Chinese 664 Academy of Sciences. We gratefully acknowledge all participants of UKB, AoU, MGBB and

KFSH&RC for their contributions, without whom this research would not have been possible. We also thank the National Institutes of Health's AoU Research Program, the UKB resource, the MGB team and KFSH&RC team, for making available the participant data examined in this study. Further, we acknowledge the dedication and expertise of the research coordinators and the comprehensive Biobank team, whose efforts in participant enrollment and data collection were indispensable.

671

672 Author contributions

673

Concept and design: M.S.K, Q.C., P.T.E., A.C.F. and M.W.. Acquisition, analysis or interpretation 674 675 of data: M.S.K, Q.C., Y.S., X.Y., S.W., L.C.W., S.M.J.C., S.K., X.Y., K.Y., X.C., R.Z., W.Y., S.L., 676 Z.L., A.C.F. and M.W. Drafting of the manuscript: M.S.K, Q.C., Y.S., A.C.F. and M.W. Critical important 677 revision of the manuscript for content: Z.L., F.A., P.N. 678

- 679 Declaration of interests
- 680

681 P.T.E. has received sponsored research support from Bayer AG, IBM Health, Bristol Myers 682 Squibb and Pfizer and Novo Nordisk. P.T.E. has also served on advisory boards or consulted for 683 Bayer AG, MyoKardia, and Novartis. P.N. reports research grants from Allelica, Amgen, Apple, 684 Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, 685 AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli 686 Lilly & Co, Esperion Therapeutics, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, 687 Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal employment at 688 689 Vertex Pharmaceuticals, all unrelated to the present work. A.C.F. reports being co-founder of 690 Goodpath, serving as scientific advisor to MyOme and HeartFlow, and receiving a research grant 691 from Foresite Labs. The remaining authors declare no competing interests.

- 692
- 693
- 694
- 695
- 696
- 697
- 698
- 699
- 700
- 701 702

703

- 704
- 705
- 706
- 707

708 References:

- 709
- 1. Ng, A. C., Delgado, V., Borlaug, B. A. & Bax, J. J. Diabesity: the combined burden of obesity
- and diabetes on heart disease and the role of imaging. *Nat. Rev. Cardiol.* **18**, 291–304
- 712 (2021).
- 2. Chadt, A., Scherneck, S., Joost, H.-G. & Al-Hasani, H. Molecular links between obesity and
 diabetes: "diabesity". (2015).
- 3. Ingelsson, E. & McCarthy, M. I. Human genetics of obesity and type 2 diabetes mellitus: past,
- present, and future. *Circ. Genomic Precis. Med.* **11**, e002090 (2018).
- 4. Coral, D. E. *et al.* A phenome-wide comparative analysis of genetic discordance between
- 718 obesity and type 2 diabetes. *Nat. Metab.* **5**, 237–247 (2023).
- 5. Fahed, A. C., Philippakis, A. A. & Khera, A. V. The potential of polygenic scores to improve
 cost and efficiency of clinical trials. *Nat. Commun.* 13, 2922 (2022).
- 6. Hao, L. *et al.* Development of a clinical polygenic risk score assay and reporting workflow.
- 722 Nat. Med. 28, 1006–1013 (2022).
- 723 7. Khera, A. V. et al. Polygenic prediction of weight and obesity trajectories from birth to
- adulthood. *Cell* **177**, 587-596. e9 (2019).
- 8. Patel, A. P. et al. A multi-ancestry polygenic risk score improves risk prediction for coronary
- 726 artery disease. *Nat. Med.* **29**, 1793–1803 (2023).
- 9. Maier, R. M. et al. Improving genetic prediction by leveraging genetic correlations among
- human diseases and traits. *Nat. Commun.* **9**, 989 (2018).
- 10. Abraham, G. *et al.* Genomic risk score offers predictive performance comparable to clinical
- risk factors for ischaemic stroke. *Nat. Commun.* **10**, 5819 (2019).
- 11. Ross, R. et al. Waist circumference as a vital sign in clinical practice: a Consensus
- 732 Statement from the IAS and ICCR Working Group on Visceral Obesity. *Nat. Rev. Endocrinol.*
- **16**, 177–189 (2020).

12. Williamson, A. *et al.* Genome-wide association study and functional characterization

identifies candidate genes for insulin-stimulated glucose uptake. *Nat. Genet.* **55**, 973–983

736 (2023).

13. Lambert, S. A. *et al.* The Polygenic Score Catalog as an open database for reproducibility

738 and systematic evaluation. *Nat. Genet.* **53**, 420–425 (2021).

- 14. Committee, A. D. A. P. P. & Committee, A. D. A. P. P. 2. Classification and diagnosis of
- diabetes: Standards of Medical Care in Diabetes—2022. *Diabetes Care* 45, S17–S38 (2022).
- 15. Lotta, L. A. *et al.* Association of genetic variants related to gluteofemoral vs abdominal fat
- distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors. Jama
- 743 **320**, 2553–2563 (2018).
- T44 16. Emdin, C. A. *et al.* Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2
 diabetes, and coronary heart disease. *Jama* **317**, 626–634 (2017).
- 17. Ye, Y. et al. Interactions between enhanced polygenic risk scores and lifestyle for
- cardiovascular disease, diabetes, and lipid levels. *Circ. Genomic Precis. Med.* **14**, e003128
- 748 (2021).
- 18. Kim, M. S. *et al.* Causal effect of adiposity on the risk of 19 gastrointestinal diseases: a
 Mendelian randomization study. *Obesity* **31**, 1436–1444 (2023).

19. Kim, M. S. et al. Association between adiposity and cardiovascular outcomes: an umbrella

- review and meta-analysis of observational and Mendelian randomization studies. *Eur. Heart*
- 753 *J.* **42**, 3388–3403 (2021).
- 20. Kim, M. S. *et al.* Association of genetic risk, lifestyle, and their interaction with obesity and
 obesity-related morbidities. *Cell Metab.* 36, 1494-1503. e3 (2024).
- 756 21. Kim, M. S. *et al.* Integration of observational and causal evidence for the association
- between adiposity and 17 gastrointestinal outcomes: An umbrella review and meta-analysis.
- 758 Obes. Rev. e13823 (2024).


- 759 22. Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E. & Ioannidis, J. P. Type 2 diabetes
- and cancer: umbrella review of meta-analyses of observational studies. *Bmj* **350**, (2015).
- 761 23. Al-Sari, N. et al. Precision diagnostic approach to predict 5-year risk for microvascular
- complications in type 1 diabetes. *EBioMedicine* **80**, (2022).
- 763 24. Aminian, A. et al. Predicting 10-year risk of end-organ complications of type 2 diabetes with
- and without metabolic surgery: a machine learning approach. *Diabetes Care* **43**, 852–859
- 765 (2020).
- 766 25. Turchin, A. *et al.* EXIST: EXamining rlsk of excesS adiposiTy—Machine learning to predict
- 767 obesity-related complications. *Obes. Sci. Pract.* **10**, e707 (2024).
- 26. Satam, H. *et al.* Next-generation sequencing technology: current trends and advancements. *Biology* 12, 997 (2023).
- 27. Kullo, I. J. *et al.* Polygenic scores in biomedical research. *Nat. Rev. Genet.* 23, 524–532
 (2022).
- 28. Lincoff, A. M. *et al.* Semaglutide and cardiovascular outcomes in obesity without diabetes.
- 773 N. Engl. J. Med. **389**, 2221–2232 (2023).
- 29. Sanyal, A. J. *et al.* A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. *N.*
- 775 Engl. J. Med. **391**, 311–319 (2024).
- 30. Perkovic, V. *et al.* Effects of semaglutide on chronic kidney disease in patients with type 2
 diabetes. *N. Engl. J. Med.* **391**, 109–121 (2024).
- 31. De Giorgi, R. et al. 12-month neurological and psychiatric outcomes of semaglutide use for
- type 2 diabetes: a propensity-score matched cohort study. *EClinicalMedicine* **74**, (2024).
- 780 32. Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection
- 781 fraction and obesity. *N. Engl. J. Med.* **389**, 1069–1084 (2023).
- 782 33. He, L. et al. Association of glucagon-like peptide-1 receptor agonist use with risk of
- 783 gallbladder and biliary diseases: a systematic review and meta-analysis of randomized

- 784 clinical trials. *JAMA Intern. Med.* **182**, 513–519 (2022).
- 34. Sodhi, M., Rezaeianzadeh, R., Kezouh, A. & Etminan, M. Risk of gastrointestinal adverse
- events associated with glucagon-like peptide-1 receptor agonists for weight loss. Jama 330,
- 787 1795–1797 (2023).
- 35. Baig, K., Dusetzina, S. B., Kim, D. D. & Leech, A. A. Medicare Part D Coverage of
- Antiobesity Medications Challenges and Uncertainty Ahead. N. Engl. J. Med. 388, 961–
- 790 963 (2023).
- 36. Wright, D. R., Guo, J. & Hernandez, I. A Prescription for Achieving Equitable Access to
- Antiobesity Medications. *JAMA Health Forum* **4**, e230493 (2023).
- 37. Committee, A. D. A. P. P. & Committee, A. D. A. P. 9. Pharmacologic approaches to
- glycemic treatment: Standards of Medical Care in Diabetes—2022. *Diabetes Care* 45, S125–
 S143 (2022).
- 38. Melson, E., Ashraf, U., Papamargaritis, D. & Davies, M. J. What is the pipeline for future
 medications for obesity? *Int. J. Obes.* 1–19 (2024).
- 39. Kachuri, L. *et al.* Principles and methods for transferring polygenic risk scores across global
 populations. *Nat. Rev. Genet.* 25, 8–25 (2024).
- 40. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat. Genet.*54, 573–580 (2022).
- 41. Ding, Y. *et al.* Polygenic scoring accuracy varies across the genetic ancestry continuum. *Nature* **618**, 774–781 (2023).
- 42. Lennon, N. J. *et al.* Selection, optimization and validation of ten chronic disease polygenic
- risk scores for clinical implementation in diverse US populations. *Nat. Med.* **30**, 480–487
 (2024).
- 43. Koyama, S. *et al.* Population-specific and trans-ancestry genome-wide analyses identify
- distinct and shared genetic risk loci for coronary artery disease. *Nat. Genet.* **52**, 1169–1177


- 809 (2020).
- 810 44. Kim, M. S. et al. Association of bariatric surgery with indicated and unintended outcomes:
- 811 An umbrella review and meta-analysis for risk–benefit assessment. Obes. Rev. 25, e13670
- 812 (2024).
- 45. Mingrone, G. et al. Bariatric-metabolic surgery versus conventional medical treatment in
- obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre,
- randomised controlled trial. *The Lancet* **386**, 964–973 (2015).
- 46. Brown, E., Heerspink, H. J., Cuthbertson, D. J. & Wilding, J. P. SGLT2 inhibitors and GLP-1
- receptor agonists: established and emerging indications. *The Lancet* **398**, 262–276 (2021).
- 47. Vogan, K. Implementing polygenic risk scores in the clinic. *Nat. Genet.* **56**, 557–557 (2024).
- 48. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
- 820 *Nature* **562**, 203–209 (2018).
- 49. Littlejohns, T. J. *et al.* The UK Biobank imaging enhancement of 100,000 participants:
- rationale, data collection, management and future directions. *Nat. Commun.* **11**, 2624 (2020).
- 50. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide
- range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
- 51. the Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype
- 826 imputation. *Nat. Genet.* **48**, 1279–1283 (2016).
- 52. The UK10K Consortium *et al.* The UK10K project identifies rare variants in health and
 disease. *Nature* 526, 82–90 (2015).
- 53. The 1000 Genomes Project Consortium *et al.* A global reference for human genetic
- 830 variation. *Nature* **526**, 68–74 (2015).
- 54. All of Us Research Program Genomics Investigators. Genomic data in the All of Us
- 832 Research Program. *Nature*, 627(8003):340-346 (2024)
- 55. Boutin, N. T. *et al.* The evolution of a large biobank at Mass General Brigham. *J. Pers. Med.*

- **12**, 1323 (2022).
- 56. Koyama, S. *et al.* Decoding Genetics, Ancestry, and Geospatial Context for Precision
- 836 Health. *medRxiv* 2023.10.24.23297096 (2023).
- 57. Bhattacharya, R. *et al.* Clonal Hematopoiesis Is Associated With Higher Risk of Stroke.
- 838 Stroke **53**, 788–797 (2022).
- 58. Shim, I. *et al.* Clinical utility of polygenic scores for cardiometabolic disease in Arabs. *Nat.*
- 840 *Commun.* **14**, 6535 (2023).
- 59. Haam, J.-H. et al. Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for
- Obesity by the Korean Society for the Study of Obesity. J. Obes. Metab. Syndr. 32, 121–129
- 843 (2023).
- 60. Hassapidou, M. *et al.* European Association for the Study of Obesity Position Statement on
- 845 Medical Nutrition Therapy for the Management of Overweight and Obesity in Adults
- 846 Developed in Collaboration with the European Federation of the Associations of Dietitians.
- 847 Obes. Facts **16**, 11–28 (2023).
- 61. Agrawal, S. *et al.* Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat
- 849 depots. *Nat. Commun.* **13**, 3771 (2022).
- 850 62. Jurgens, S. J. et al. Rare coding variant analysis for human diseases across biobanks and
- ancestries. *Nat. Genet.* **56**, 1811–1820 (2024).
- 852 63. Koenig, Z. et al. A harmonized public resource of deeply sequenced diverse human
- genomes. *Genome Res.* **34**, 796–809 (2024).
- 64. Schizophrenia Working Group of the Psychiatric Genomics Consortium et al. LD Score
- regression distinguishes confounding from polygenicity in genome-wide association studies.
- 856 *Nat. Genet.* **47**, 291–295 (2015).
- 857 65. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics* vol.
 858 36 5424–5431 (2020).

- 859 66. Band, G. & Marchini, J. BGEN: a binary file format for imputed genotype and haplotype
- 860 data. Preprint at https://doi.org/10.1101/308296 (2018).
- 861 67. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
- datasets. *GigaScience* **4**, 7 (2015).



в



UK Biobank	All of Us	MGB Biobank	KFSH&RC
(n=49,377)	(n=245,394)	(n=53,306)	(n=6,416)
European: 34,626 African: 6,842 East Asian: 1,304 South Asian: 6,605	European: 133,581 African: 56,913 East Asian: 5,706 South Asian: 3,217 Latino/admixed American: 45,035 Middle Eastern: 942	European: 44,892 African: 2,892 East Asian: 1,064 South Asian: 607 Latino/admixed American: 3,851	Middle Eastern: 6,416

864 Fig.1 | Study overview.

Overview of study (A) and MetPRS development (B). Polygenic risk scores were developed using 865 866 cohort-specific, ancestry-stratified summary statistics for 22 metabolic traits. (a) For each trait, 867 such as BMI, the optimal combination of cohort-specific, ancestry-stratified PRSs was identified 868 using stepAIC, the selected PRSs were then combined linearly to create multi-ancestry scores 869 for predicting target trait (Obesity or Type 2 diabetes). The best mixing weights (β) were calculated 870 using regression on 15.000 European participants from the UK Biobank training set (laver 1).(b) 871 The most effective combination of multi-ancestry, trait-specific PRSs was identified using stepAIC 872 for predicting target trait, and their optimal mixing weights (β) for selected PRSs were determined 873 through regression on the same dataset. The chosen PRSs were then linearly combined to 874 produce O-MetPRS and D-MetPRS (layer 2). The participants in the validation and testing set are 875 non-overlapping individuals and independent with input GWAS samples. (c) These MetPRS were 876 tested on internal (UK Biobank hold out test set) and external (All of Us, MGB Biobank, KFSH&RC) 877 datasets. The genetic predispositions to traits indicative of obesity (i.e., BMI, waist circumference, 878 and visceral adipose tissue) or T2D (i.e., fasting glucose, HbA1c, and insulin sensitivity) can 879 contribute unique insights into the multifaceted nature of metabolic dysfunction. Leveraging 880 genetic signature of related traits might capture a more comprehensive underlying metabolism 881 and enhance the overall prediction of obesity and T2D. BMI: body mass index; DM: type 2 882 diabetes; WC: waist circumference; HC: hip circumference; WHR: waist-to-hip ratio; VAT: visceral 883 adipose tissue; ASAT: abdominal subcutaneous adipose tissue; GFAT: gluteofemoral adipose 884 tissue; vatGfatRatio: VAT/GFAT ratio; asatGfatRatio: ASAT/GFAT ratio; vatAsatRatio: VAT/ASAT 885 ratio; 2hG: 2-hour glucose; ISI: insulin sensitivity index; FG: fasting glucose; FI: fasting insulin; 886 cT1: MRI-based Liver iron corrected T1; NAFLD: non-alcoholic fatty liver disease.

887 888

889

890

891

892


893

894

895

896


897



898


Fig.2 | Genetic correlations across 22 metabolic traits and measures associated with insulin resistance.

901 Genetic correlations were obtained from cross-trait LD-score regression using sex-combined 902 summary statistics. Stumvoll insulin sensitivity index (ISI) is inversely proportional to insulin 903 resistance as it measures insulin sensitivity. Genetic correlation heatmap matrix remained 904 significant after multiple testing corrections are indicated by asterisks. BMI: body mass index; DM: 905 type 2 diabetes; WC: waist circumference; HC: hip circumference; WHR: waist-to-hip ratio; ASAT: 906 abdominal subcutaneous adipose tissue; VAT: visceral adipose tissue; GFAT: gluteofemoral 907 adipose tissue; asatGfatRatio: ASAT/GFAT ratio; vatAsatRatio: VAT/ASAT ratio; vatGfatRatio: 908 VAT/GFAT ratio; 2hG: 2-hour glucose; FG: fasting glucose; FI: fasting insulin; cT1: MRI-based 909 Liver iron corrected T1; ISI: insulin sensitivity index; NAFLD: non-alcoholic fatty liver disease.



911 Fig.3 | Internal validation of MetPRS performance in UK Biobank hold-out test set

The OR/SD with 95% CI and prevalence (%) across percentile bins were assessed for obesity (A,B) and T2D (C,D) in UK Biobank hold out test set (n = 49,377). MetPRS was compared with all obesity and T2D PRSs published in PGS Catalog (https://www.pgscatalog.org/) that had not included UK Biobank in score development. We then selected highest-performing score among published studies for obesity (PGS000027 - GPS_BMI - Khera AV et al) and T2D (PGS001357 -T2D AnnoPred PRS - Ye et al), and compared them with MetPRS by grouping according to polygenic risk score percentiles. Obesity was defined as a BMI of 25 Kg/m² or above for East Asians, and 30 Kg/m² or above for all other populations. O-MetPRS: obesity MetPRS; D-MetPRS: T2D MetPRS; OR/SD: odds ratio per increase in 1 standard deviation.




954

955

956 Fig.4 | External validation of MetPRS in multiple ancestries.

The OR/SD for prevalent obesity (A) and T2D (B) was assessed for each polygenic risk score in a logistic regression model adjusted for age, sex, genotyping array and the first ten principal components of ancestry in external datasets: All of Us (n = 245,394), MGB Biobank (n = 53,306), and KFSH&RC cohort (n = 6,416). MetPRS was compared with top 5 obesity and T2D scores in PGS Catalog. Polygenic risk scores that consistently ranked highly across external datasets were selected as comparators (top 5), excluding any scores that incorporated any test cohort (i.e., All


963	of Us) in their score development. Obesity was defined as a BMI of 25 Kg/m ² or above for East
964	Asians, and 30 Kg/m ² or above for all other populations. AoU: All of Us; MGBB: Massachusetts
965	General Brigham Biobank; Admixed: Latino/admixed American; O-MetPRS: obesity MetPRS; D-
966	MetPRS: T2D MetPRS; OR/SD: odds ratio per increase in 1 standard deviation of PRS score.
967	
968	
969	
970	
971	
972	
973	
974	
975	
976	
970 977	
978	
979	
980	
981	
982	
983	
983 984	
985	
985 986	
980 987	
988 988	
989 989	
989 990	
990 991	
991 992	
992 993	
993 994	
995	
996	
990 997	
998	
999 999	
1000	
1000	
1001	
1002	
1003	
1004	



1005

1006 Fig.5 | Prediction of obesity and diabetes-related morbidities.

1007 The top decile of the MetPRS distribution was identified as "carriers," and their risk was assessed 1008 against the rest of the cohort. Risk was estimated using a Cox proportional hazards regression 1009 model, adjusted for age, sex, genotyping array and the first ten principal components of ancestry. The performance of O-MetPRS and the other top scores in predicting obesity-related morbidities 1010 1011 was evaluated (A), and their corresponding rank frequencies across morbidities were summarized 1012 (B). The performance of D-MetPRS and other top scores in predicting diabetes-related morbidities 1013 and complications was evaluated (C), and their corresponding rank frequencies across 1014 morbidities and complications were summarized (D). The forest plot for the other conditions refers to Extended Data Fig.5. Full list of morbidities is provided in Supplementary Table 14. 1015



1016 1017

1018Fig.6 | Risk for incident GLP-1 receptor agonist prescription and metabolic-bariatric1019surgery according to MetPRS strata in MGB Biobank participants free of obesity and T2D1020at the baseline

1021 The 37,329 participants without baseline obesity and T2D were included for analysis. Cumulative 1022 incidence of GLP-1 receptor agonist prescription (A) and metabolic-bariatric surgery (B) stratified by O-MetPRS; cumulative incidence of GLP-1 receptor agonist prescription (C) and metabolic-1023 1024 bariatric surgery (D) stratified by D-MetPRS. The risks were estimated using Cox proportional hazards regression model adjusted for age, sex, and the first ten principal components of ancestry 1025 1026 in a 37,329 population without obesity and T2D at the baseline in MGB Biobank. GLP-1 receptor 1027 agonist prescription and metabolic-bariatric surgery were selected as clinical endpoints as they 1028 are interventions indicated for obesity or diabetes or both. 1029